GCPRs Targeted Drug Discovery Summit

GPCRs-targeted drug discovery continues to gain exponential momentum, with advances in screening tools, characterization of dynamic confirmations and basic GPCR biology, including orphan receptors. Coupled with numerous strategic collaboration and investment, the GPCR field is fuelling for the clinical progression of next-generation small molecules and biologics across a spectrum of indications and previously undrugged GPCR targets.

Owing to this, the Annual GPCRs-Targeted Drug Discovery Summit returns for its 3rd year as the world's only and most comprehensive industry dedicated GPCR forum. Bringing two brand new specialized tracks of content (Target ID and Validation and Hit ID and Optimization), don't miss out on your ultimate chance to unite with 100+ GPCR experts devoted to accelerating the discovery of new, transformative small molecules and biologics.

URLs:
Website: https://go.evvnt.com/2056320-0?pid=10018
Tickets: https://go.evvnt.com/2056320-2?pid=10018
Brochure: https://go.evvnt.com/2056320-3?pid=10018

Prices:
Drug Developer Pricing - Conference + Focus Day: USD 4297.00,
Drug Developer Pricing - Conference Only: USD 2999.00,
Discounted Pricing - Conference + Focus Day: USD 3697.00,
Discounted Pricing - Conference Only: USD 2599.00,
Vendor Pricing - Conference + Focus Day: USD 5197.00,
Vendor Pricing - Conference Only: USD 3699.00

Speakers: Adnan Sljoka Principal Investigator RIKEN Center for Integrative Medical Sciences, Ajay Yekkirala Co-Founder, Senior Vice President and Head of Discovery Superluminal Medicines Inc, Andreas Busch Senior Scientist - Protein Science Confo Therapeutics, Aurélien Rizk Co-Founder and Chief scientific officer InterAx Biotech, Barbara Cipriani Vice President and Head of Biology Pathios Therapeutics, Benjamin Chen Managing Partner Panacea Ventures, Callum Dickson Senior Principal Scientist Novartis AG, Cheng Zhang Associate Professor University of Pittsburgh, Chris de Graaf Senior Director, Head of Computational Chemistry Sosei Heptares, Chris Roth Vice President - Research Abilita Therapeutics, Chris Roth Vice President - Research Abilita Therapeutics, Clare Doris Chief Operating Officer Cumulus Oncology, Dale Starkie Director DJS Antibodies/AbbVie, Edward van Wezel Managing Partner Biogeneration Ventures, Erik Hembre Associate Vice President Eli Lilly and Co., Faiz Ahmad Mohammed Senior Advisor Eli Lilly and Co., Graeme Milligan Gardiner Professor of Biochemistry University of Glasgow, Irina Tikhonova Reader in Molecular Modelling Queen's University Belfast, Jean-Philippe Fortin Research Fellow Pfizer, Josephine (Pina) Cardarelli Chief Scientific Officer and President of US Site Operations GPCR Therapeutics, Joshua Ziarek Associate Professor of Pharmacology Northwestern University, Laetitia Comps-Agrar Senior Principal Scientist - Biochemical and Cellular Pharmacology Genentech, Mike Goguen Founder and Managing Director Two Bear Capital, Niklas Larsson Principal Scientist AstraZeneca, Oliver Hartley Vice President - Drug Discovery Orion Biotechnology, Peter McNamara Chief Scientific Officer Tectonic Therapeutic, Reza Vafabakhsh Assistant Professor Northwestern University, Robin Löving Chief Scientific Officer Salipro Biotech AB, Seungil Han Research Fellow and Head of Cryo-EM Structural Biology Lab Pfizer, Shu-Chen Lu Scientific Associate Director Amgen Inc., Stacey Southall Vice President, Head of Platform Sosei Heptares, Stephan Schann VP Research Domain Therapeutics, Steve Gardner Chief Executive Officer PrecisionLife Ltd., Yue Liu Associate Director Generate Biomedicines, Inc, Zoe Hughes Vice President and Head of Biology Gilgamesh Pharmaceutical